COMMUNIQUÉS West-GlobeNewswire

Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025
01/03/2025
- Greatly improved patient quality of life and reduced disease impact in patients with CSU and CIndU - - 82% of CSU patients reported that symptoms no longer had an impact on their quality of life at Week 52 - - 60% of [...]
International Myeloma Foundation (IMF) Celebrates Myeloma Milestones for 2025 Myeloma Action Month
01/03/2025
STUDIO CITY, Calif., March 01, 2025 (GLOBE NEWSWIRE) -- Myeloma Action Month is an annual global awareness campaign that takes place every March to raise awareness and inspire action for multiple myeloma—a blood cancer [...]
Prime Biome Reviews: Massive Breakthrough in Skin Problems, Premature Aging and Gut Health
01/03/2025
ST. PETERSBURG, Fla., Feb. 28, 2025 (GLOBE NEWSWIRE) -- In recent months, a new supplement called Prime Biome has been making waves in the health and wellness industry. Positioned as a gut and skin support formula, it [...]
Premier Health Reports 2025 First Quarter Results
28/02/2025
MONTRÉAL, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA ) (the “ Corporation ”), a leading Canadian Healthtech company, announces it has filed its unaudited Quarterly Consolidated Financial [...]
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
28/02/2025
LEXINGTON, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a [...]
4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
28/02/2025
Presented positive interim data through 52 weeks and beyond for 4D-150 in wet AMD from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patient populations and continued [...]
Vincerx Pharma Announces Termination of Reverse Merger Term Sheet and Evaluation of Strategic Alternatives
28/02/2025
SAN MATEO, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced that the previously signed binding Term Sheet between Vincerx, Oqory, Inc., and Vivasor, Inc. for a reverse merger [...]
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
28/02/2025
Company Announcement COPENHAGEN, Denmark; February 28, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document [...]
Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update
28/02/2025
Pivotal Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ (laromestrocel) in Hypoplastic Left Heart Syndrome (HLHS), a rare pediatric disease and orphan-designated indication, has achieved more than 90% [...]
Aclarion, Inc. Announces Adjournment of Special Meeting of Stockholders
28/02/2025
Meeting adjourned to Wednesday, March 5, 2025 at 9:30 a.m. Mountain Time BROOMFIELD, Colo., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ: ACON) (NASDAQ: ACONW), a healthcare [...]
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
28/02/2025
Company Announcement COPENHAGEN, Denmark; February 28, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 614,676 restricted stock units to members of management and employees of the [...]
Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025
28/02/2025
Webcast to be held Monday, March 3rd at 8:30 a.m. ET SAN FRANCISCO and BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel [...]
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
28/02/2025
REDWOOD CITY, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum’s Board of Directors granted inducement awards consisting [...]
Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy
28/02/2025
Tevogen Bio is focused on delivering affordable, safe, and easy-to-administer T cell therapies. The company’s ExacTcell™ technology enabled a proof-of-concept trial with highly positive results, published in Blood [...]
Groupe PAT : Hausse du Chiffre d’Affaires Combiné 2024
28/02/2025
Vandœuvre-lès-Nancy, le 28 février 2025 - 18 : 30 (CET) Communiqué de presse Pour diffusion immédiate Hausse du Chiffre d’Affaires Combiné 2024 Chiffre d’affaires combiné non audité en progression à 2,9 M€ (+26%/2023) [...]
Valneva Receives EMA’s Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ®
28/02/2025
If granted, IXCHIQ ® will become the first vaccine against the chikungunya virus (CHIKV) available in the EU for adolescents 12 years of age and older Saint Herblain (France), February 28, 2025 – Valneva SE (Nasdaq: [...]
Valneva reçoit un avis positif du CHMP de l’EMA pour élargir l’indication de son vaccin contre le chikungunya IXCHIQ® aux adolescents
28/02/2025
Si l’avis est validé par la Commission Européenne, IXCHIQ ® pourrait devenir le premier vaccin contre le chikungunya disponible en Europe pour les adolescents âgés de 12 ans et plus Saint Herblain (France), le 28 [...]
Bavarian Nordic Receives Marketing Authorization in Europe for Chikungunya Vaccine for Persons Aged 12 and Older
28/02/2025
First chikungunya vaccine approved in Europe for persons as young as 12 years old. On track for launch in key European markets in the first half of 2025. COPENHAGEN, Denmark, February 28, 2025 – Bavarian Nordic A/S (OMX [...]
Orion Corporation: Managers’ transactions – Outi Vaarala
28/02/2025
ORION CORPORATION MANAGERS’ TRANSACTIONS 28 FEBRUARY 2025 at 17.45 EET Orion Corporation: Managers’ transactions – Outi Vaarala Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) [...]

Pages